You are here

Plinabulin/Docetaxel Combo Mitigates Safety Concerns of Docetaxel in Lung Cancer Patients

Phase 2 study shows significant reduction in neutropenia

Docetaxel is approved for use in patients with non–small-cell lung cancer (NSCLC) after the failure of first-line chemotherapy. The treatment, however, has an unfavorable toxicity profile that limits its use. An investigational therapy, plinabulin (BeyondSpring Pharmaceuticals), is being developed in combination with docetaxel to provide a regimen with an improved safety profile. Plinabulin is a first-in-class small-molecule vascular-disruptive agent with immuno-oncology effects.

A phase 2 study compared the safety and efficacy of the plinabulin/docetaxel combination (n = 90) with that of docetaxel alone (n = 73) in patients with NSCLC entering second- or third-line therapy. Plinabulin was administered intravenously at 20 mg/m2 (n = 40) or 30 mg/m2 (n = 50), and docetaxel was administered at 75 mg/m2 (n = 73).

Efficacy results from this study were presented at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO). The plinabulin/docetaxel combination provided a significant duration-of-response benefit over docetaxel alone (12.7 months vs. 1.5 months, respectively; P < 0.05).

The investigators are now preparing to present safety results for the plinabulin/docetaxel combination at the next ASCO meeting, to be held on June 3–7 in Chicago.

In the phase 2 study, the combination treatment mitigated some of the toxicities of docetaxel monotherapy. Plinabulin/docetaxel provided significant (P < 0.01) reductions in grade-3 or grade-4 neutropenia (7% vs. 25%) and in asthenia (13% vs. 28%); significantly reduced the use of granulocyte-colony stimulating factor (G-CSF) (14% vs. 29%); and significantly reduced docetaxel dose reductions due to toxicity (6% vs. 20%). The neutropenia benefit was likely due to the plinabulin-induced release of cytokines, such as interleukin-1 (IL-1) and IL-6, which are known to increase the neutrophil count.

A global phase 3 study of the plinabulin/docetaxel combination compared with docetaxel alone is currently under way in the United States, China, Australia, and New Zealand. 

Plinabulin is administered by a 30-minute intravenous infusion. It is given 60 minutes after the completion of a docetaxel infusion.

Sources: PR Newswire; May 26, 2016; and ASCO Abstract; May 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs